dr. tam on zanubrutinib vs ibrutinib research in mantle cell lymphoma
Published 4 years ago • 254 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
0:44
dr. tam on zanubrutinib approval in mcl
-
1:56
dr. tam on the combination of ibrutinib plus venetoclax in mantle cell lymphoma
-
1:08
dr. tam on the toxicities of ibrutinib plus venetoclax in mcl
-
0:47
alpine results: zanubrutinib vs. ibrutinib in cll
-
1:08
dr. tam on the toxicity of ibrutinib plus venetoclax in mcl
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
1:08
dr. song on zanubrutinib activity in relapsed/refractory mcl
-
0:58
dr. leslie on the benefits with zanubrutinib in mcl
-
0:55
zanubrutinib in mantle cell lymphoma: updated safety and efficacy data
-
3:47
new and emerging btk inhibitors in mantle cell lymphoma
-
1:32
dr. zelenetz on zanubrutinib research in mcl
-
2:00
ibrutinib in mantle cell lymphoma - an update
-
1:22
dr. leslie on sequencing zanubrutinib in mcl
-
7:11
selection of a btk inhibitor in relapsed/refractory mcl
-
0:48
real-world results in the uk for ibrutinib at first relapsed for mcl
-
1:46
btk inhibitors continue to improve survival in mantle cell lymphoma
-
5:23
constantine tam: zanubrutinib active in treatment-naïve cll/sll
-
4:55
ibrutinib in relapsed mantle cell lymphoma
-
2:09
dr. sharman on the phase iii results of the genuine study in cll